The New England Journal of Medicine DECEMBER 16, 2021

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico (PREVENT-19)

Dunkle LM, Kotloff KL, Gay CL, et al. (PREVENT-19 Study Group)

Bottom Line

In the Phase 3 PREVENT-19 trial, the protein-based, adjuvanted NVX-CoV2373 vaccine demonstrated 90.4% efficacy against symptomatic COVID-19 and 100% protection against moderate-to-severe disease in a diverse adult population in the U.S. and Mexico.

Key Findings

1. The NVX-CoV2373 vaccine achieved a primary efficacy of 90.4% (95% CI, 82.9 to 94.6) against PCR-confirmed symptomatic COVID-19 occurring at least 7 days after the second dose.
2. The trial observed 100% vaccine efficacy (95% CI, 87.0 to 100) against moderate or severe COVID-19 disease, with all 14 cases of moderate-to-severe disease occurring in the placebo group.
3. In the full-analysis population, the infection rate was 21.2 cases per 1,000 person-years in the vaccine group compared to 51.9 per 1,000 person-years in the placebo group.
4. Vaccine efficacy remained high at 91.0% among participants defined as high-risk for severe COVID-19 complications.

Study Design

Design
RCT
Observer-Blind
Sample
29,949
Patients
Duration
Approx. 3 mo
Median
Setting
Multicenter, US/Mexico
Population Adults aged 18 years and older without evidence of prior SARS-CoV-2 infection at baseline
Intervention Two doses of 5 mcg recombinant SARS-CoV-2 spike protein nanoparticle vaccine with 50 mcg Matrix-M1 adjuvant administered 21 days apart
Comparator Two doses of saline placebo administered 21 days apart
Outcome PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 7 days after the second dose

Study Limitations

The trial was conducted primarily before the widespread emergence of the Delta and Omicron variants, limiting the ability to assess efficacy against these highly transmissible strains.
The study duration and timing of the primary efficacy analysis resulted in a relatively short follow-up period, precluding assessment of long-term durability of protection.
The trial did not specifically evaluate efficacy against asymptomatic transmission or viral shedding.

Clinical Significance

The results established NVX-CoV2373 as a highly effective, alternative vaccination platform. Its reliance on well-understood protein-based technology and its storage stability at standard refrigeration temperatures (2–8°C) provided a significant public health advantage for distribution in regions with complex cold-chain logistics.

Historical Context

During the early stage of the COVID-19 pandemic, mRNA vaccine platforms dominated early emergency use authorizations. The PREVENT-19 trial provided pivotal evidence for a protein subunit nanoparticle vaccine, offering a conventional technological approach that addressed vaccine hesitancy in populations wary of novel mRNA technologies and provided a critical tool for global vaccination efforts.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

Explain the immunological mechanism of action for NVX-CoV2373 and how the inclusion of the Matrix-M adjuvant differentiates its immune profile from traditional inactivated virus vaccines.

Key Response

NVX-CoV2373 is a recombinant nanoparticle vaccine containing the spike protein in its prefusion conformation. Unlike inactivated vaccines which present the whole virus, this target-specific approach, coupled with a saponin-based adjuvant (Matrix-M), specifically enhances the recruitment of antigen-presenting cells and promotes a Th1-biased immune response, which is critical for effective viral clearance and avoiding vaccine-associated enhanced respiratory disease.

Resident
Resident

A patient with a history of PEG (polyethylene glycol) allergy expresses interest in COVID-19 vaccination but is wary of mRNA technology. Based on the PREVENT-19 trial, how does NVX-CoV2373 serve as a clinically appropriate alternative?

Key Response

NVX-CoV2373 uses a recombinant protein platform similar to the Hepatitis B and HPV vaccines, which does not contain PEG (using Polysorbate 80 instead). Residents should recognize that with 90.4% efficacy against symptomatic disease and 100% protection against moderate-to-severe disease in the trial, it provides a high-efficacy option for those with contraindications to mRNA components or those preferring a more traditional vaccine technology.

Fellow
Fellow

The PREVENT-19 trial reported high efficacy during a period when the Alpha (B.1.1.7) variant was dominant; how should the observed T-cell responses in the NVX-CoV2373 cohort be evaluated regarding their potential for cross-protection against later immune-escape variants like Omicron?

Key Response

Fellows must integrate the trial's cellular immunity data with evolving variant landscapes. While neutralizing antibody titers often drop against variants with mutations in the receptor-binding domain (RBD), the protein-based platform in PREVENT-19 demonstrated robust CD4+ and CD8+ T-cell responses that target epitopes across the entire spike protein, many of which are conserved across variants, potentially maintaining protection against severe disease even when symptomatic efficacy wanes.

Attending
Attending

Considering the logistics of global vaccine equity and the results of PREVENT-19, how does the stability profile of NVX-CoV2373 facilitate a 'heterologous prime-boost' strategy in populations with limited cold-chain infrastructure?

Key Response

NVX-CoV2373 is stable at standard refrigeration temperatures (2°C to 8°C), unlike mRNA vaccines. Evidence from subsequent studies following the trial suggests that using a protein-based vaccine as a booster after an mRNA or viral-vector primary series can broaden the immune response. Attendings can use this to teach that vaccine choice is not just about initial efficacy, but about durability and the pragmatics of public health implementation.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

Critique the impact of the 'blinded crossover' design implemented in the PREVENT-19 trial on the statistical power to detect late-onset adverse events and the long-term durability of the primary endpoint.

Key Response

The blinded crossover was ethically necessary once vaccines became widely available, but it truncated the placebo-controlled follow-up period. From a research methodology perspective, this limits the ability to calculate a true 'hazard ratio' for infection over time and creates a 'healthy vaccinee' bias in long-term safety data, as the original placebo group's period of risk is essentially censored early.

Journal Editor
Journal Editor

The PREVENT-19 trial achieved high diversity in its North American cohort (nearly 45% from racial and ethnic minorities); why is this demographic representation a critical factor in the editorial assessment of the study's external validity and internal rigor?

Key Response

Editors look for generalizability. By ensuring the participant pool reflected the populations most disproportionately affected by the pandemic, the study reduces the threat of 'selection bias' and ensures that the efficacy data (90.4%) is applicable to a broad real-world population. It also strengthens the safety profile by capturing potential rare reactions across a genetically and socioeconomically diverse group.

Guideline Committee
Guideline Committee

Based on the 100% efficacy against moderate-to-severe disease in PREVENT-19, how should NVX-CoV2373 be integrated into ACIP or WHO recommendations for immunocompromised populations compared to current mRNA-based 'preferred' status?

Key Response

Current guidelines (like those from the ACIP) list NVX-CoV2373 as a valid option. However, because the PREVENT-19 trial excluded many severely immunocompromised individuals, guideline committees must weigh the high efficacy seen in the general cohort against the potential need for a three-dose primary series, similar to mRNA protocols, to achieve comparable immunogenicity in vulnerable populations, referencing the 'Strength of Recommendation' based on available evidence-based gap-filling.

Clinical Landscape

Noteworthy Related Trials

2020

COVE Trial

n = 30,420 · NEJM

Tested

mRNA-1273 vaccine (Moderna)

Population

Healthy adults

Comparator

Placebo

Endpoint

Symptomatic COVID-19

Key result: The vaccine showed 94.1% efficacy in preventing COVID-19 illness.
2020

BNT162b2 Phase 3 Trial

n = 43,548 · NEJM

Tested

BNT162b2 vaccine (Pfizer-BioNTech)

Population

Adults 16 years and older

Comparator

Placebo

Endpoint

Symptomatic COVID-19

Key result: Two doses of BNT162b2 provided 95% protection against COVID-19.
2021

ENSEMBLE Trial

n = 43,783 · NEJM

Tested

Ad26.COV2.S vaccine (Janssen)

Population

Adults 18 years and older

Comparator

Placebo

Endpoint

Moderate to severe COVID-19

Key result: The single-dose vaccine demonstrated 66.9% efficacy against moderate to severe COVID-19 at 14 days.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis